Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier

•Cytoreductive surgery (CRS) followed by HIPEC is a feasible treatment for patients with advanced endometrial cancer.•The subgroup of patients with peritoneal metastases from endometrial cancer, in whom a greater benefit was obtained in terms of RFS are:oPatients without preoperative chemotherapy.oPatients in whom surgery was completed with limited maneuvers (<3 peritonectomies, without supramesocolic surgery),oPatients receiving HIPEC based on cisplatin and without lymphatic dissemination.